Skip to main content

Advertisement

Log in

Postmenopausal estrogen therapy and depressive symptoms in older women

Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

BACKGROUND: Evidence regarding the effect of postmenopausal estrogen therapy on mood is limited.

METHODS: To determine whether postmenopausal estrogen therapy is associated with fewer depressive symptoms in elderly women, we conducted a cross-sectional study of 6,602 white women ages 71 years or older who were recruited from population-based listings in Baltimore, Md; Minneapolis, Minn; Portland, Ore; and the Monongahela Valley, Pa. Use of estrogen and progestin was determined by interview. Participants completed the Geriatric Depression Scale short form (GDS) and were considered depressed if they reported 6 or more of 15 possible symptoms of depression.

RESULTS: A total of 6.3% (72/1,150) of current estrogen users, 7.2% (142/1,964) of past estrogen users, and 9.0% (313/3,488) of never users reported 6 or more symptoms of depression (P=.004). Current estrogen users had a decreased risk of reporting 6 or more depressive symptoms, compared with not current (past or never) users of estrogen (odds ratio [OR], 0.7; 95% CI, 0.5 to 0.9; P=.01), adjusted for living alone, bilateral oophorectomy, current smoking, physical activity, social network, self-perceived health, cognitive function, functional status, and antidepressant use. However, excluding women who use estrogen or progestin alone, we were unable to find an association between current use of combined estrogen plus progestin therapy and depressive symptoms (adjusted OR, 0.8; 95% CI, 0.5 to 1.4; P=.5).

CONCLUSIONS: This cross-sectional study found that current use of unopposed estrogen was associated with a decreased risk of depressive symptoms in older women. Additional studies are needed to understand the effect of combined estrogen and progestin therapy on the prevalence of depressive symptoms in older women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Depression Guideline Panel. Depression in Primary Care. Vol 1: Detection and Diagnosis. Clinical Practice Guideline. Washington, DC: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993. AHCPR 93-0550.

  2. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry. 1998;44:798–811.

    Article  PubMed  CAS  Google Scholar 

  3. Jensvold MF, Halbreich U, Hamilton JA, eds. Psychopharmacology and Women: Sex, Gender and Hormones. Washington, DC: American Psychiatric Press; 1996.

    Google Scholar 

  4. Stahl SM. Basic psychopharmacology of antidepressants, part 2: estrogen as an adjunct to antidepressant treatment. J Clin Psychiatry. 1998;4:15–24.

    Google Scholar 

  5. Dennerstein L, Burrows GD, Hyman GJ, Sharpe K. Hormone therapy and affect. Maturitas. 1979;1:247–59.

    Article  PubMed  CAS  Google Scholar 

  6. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology. 1985;10:325–35.

    Article  PubMed  CAS  Google Scholar 

  7. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991;78:991–5.

    PubMed  CAS  Google Scholar 

  8. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy—a placebo-controlled study. Int J Fertil Menopausal Stud. 1995;40:73–8.

    PubMed  CAS  Google Scholar 

  9. George GC, Utian WH, Beaumont PJ, Beardwood CJ. Effect of exogenous oestrogens on minor psychiatric symptoms in postmenopausal women. S Afr Med J. 1973;47:2387–8.

    PubMed  CAS  Google Scholar 

  10. Coppen A, Bishop M, Beard RJ. Effects of piperazine oestrone sulphate on plasma tryptophan, oestrogens, gonadotrophins and psychological functioning in women following hysterectomy. Curr Med Res Opin. 1977;4:29–36.

    Google Scholar 

  11. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol. 1977;4:31–47.

    PubMed  CAS  Google Scholar 

  12. Strickler RC, Borth R, Cecutti A, et al. The role of oestrogen replacement in the climacteric syndrome. Psychol Med. 1977;7:631–9.

    PubMed  CAS  Google Scholar 

  13. Thomson J, Oswald I. Effect of oestrogen on the sleep, mood, and anxiety of menopausal women. Br Med J. 1977;2:1317–9.

    PubMed  CAS  Google Scholar 

  14. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract. 1981;31:134–40.

    PubMed  CAS  Google Scholar 

  15. Montgomery JC, Appleby L, Brincat M, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet. 1987;1:297–9.

    Article  PubMed  CAS  Google Scholar 

  16. Saletu B, Brandstatter N, Metka M, et al. Double-blind, placebocontrolled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology. 1995;122:321–9.

    Article  PubMed  CAS  Google Scholar 

  17. Prange AJ. Estrogen may well affect response to antidepressant. JAMA. 1972;219:143–4.

    Google Scholar 

  18. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550–4.

    PubMed  CAS  Google Scholar 

  19. Shapira B, Oppenheim G, Zohar J, Segal M, Malach D, Belmaker RH. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry. 1985;20:576–9.

    Article  PubMed  CAS  Google Scholar 

  20. Zohar J, Shapira B, Oppenheim G, Ayd FJ, Belmaker RH. Addition of estrogen to imipramine in female-resistant depressives. Psychopharmacol Bull. 1985;21:705–6.

    PubMed  CAS  Google Scholar 

  21. Oppenheim G, Zohar J, Shapiro B, et al. The role of estrogen in treating resistant depression. In: Zohar J, Belmaker RH, eds. Treating Resistant Depression. Boston Mass: PMA Publishing; 1987:357–63.

    Google Scholar 

  22. Palinkas LA, Barrett-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol. 1992;80:30–6.

    PubMed  CAS  Google Scholar 

  23. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199–208.

    Article  Google Scholar 

  24. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-anlysis. Obstet Gynecol. 1995;85:304–13.

    Article  PubMed  CAS  Google Scholar 

  25. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord. 1988;14:177–87.

    Article  PubMed  CAS  Google Scholar 

  26. Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA. 1990;263:665–8.

    Article  PubMed  CAS  Google Scholar 

  27. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24:709–11.

    PubMed  CAS  Google Scholar 

  28. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clinical Gerontologist. 1986;5:165–73.

    Article  Google Scholar 

  29. Gerety MB, Williams J Jr, Mulrow CD, et al. Performance of casefinding tools for depression in the nursing home: influence of clinical and functional characteristics and selection of optimal threshold scores. J Am Geriatr Soc. 1994;42:1103–9.

    PubMed  CAS  Google Scholar 

  30. Paffenbarger RSJ, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol. 1978;108:161–75.

    PubMed  Google Scholar 

  31. Lubben JE. Assessing social networks among elderly populations. Fam Comm Health. 1988;11:42–52.

    Google Scholar 

  32. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign, Ill: Human Kinetics Books; 1988.

    Google Scholar 

  33. Wechsler D, Wechsler Adult Intelligence Scale-Revised. New York, NY: Psychological Corporation; 1988.

    Google Scholar 

  34. Pincus T, Summey JA, Soraci S Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Standford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346–53.

    Article  PubMed  CAS  Google Scholar 

  35. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab. 1991;72:336–43.

    Article  PubMed  CAS  Google Scholar 

  36. Arpels JC. The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. J Reprod Med. 1996;41:633–9.

    PubMed  CAS  Google Scholar 

  37. Guicheney P, Leger D, Barrat J, et al. Platelet serotonin content and plasma tryptophan in peri- and postmenopausal women: variations with plasma oestrogen levels and depressive symptoms. Eur J Clin Invest. 1988;18:297–304.

    Article  PubMed  CAS  Google Scholar 

  38. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y, Moriarty D. Effects of estrogen therapy on plasma MAO activity and EEG driving responses of depressed women. Am J Psychiatry. 1972;128:1492–8.

    PubMed  CAS  Google Scholar 

  39. Price WA, Giannini AJ, Antidepressant effects of estrogen. J Clin Psychiatry. 1985;46:506.

    PubMed  CAS  Google Scholar 

  40. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44:839–50.

    Article  PubMed  CAS  Google Scholar 

  41. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol. 1996;16:325–44.

    Article  PubMed  CAS  Google Scholar 

  42. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry. 1995;37:434–41.

    Article  PubMed  CAS  Google Scholar 

  43. Oppenheim G. Estrogen in the treatment of depression: neuropharmacological mechanisms. Biol Psychiatry. 1983;18:721–5.

    PubMed  CAS  Google Scholar 

  44. Kumar MS, Chen CL, Muther TF. Changes in the pituitary and hypothalamic content of methionine-enkephalin during the estrous cycle of rats. Life Sci. 1979;25:1687–96.

    Article  PubMed  CAS  Google Scholar 

  45. Saletu B, Brandstatter N, Metka M, et al. Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. Maturitas. 1996;23:91–105.

    Article  PubMed  CAS  Google Scholar 

  46. Coope J. Hormonal and non-hormonal interventions for menopausal symptoms. Maturitas. 1996;23:159–68.

    Article  PubMed  CAS  Google Scholar 

  47. McEwen BS, Biegon A, Davis PG, et al. Steroid hormones: humoral signals which alter brain cell properties and functions. Recent Prog Horm Res. 1982;38:41–92.

    PubMed  CAS  Google Scholar 

  48. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597–606.

    PubMed  CAS  Google Scholar 

  49. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 1990;163:1438–44.

    PubMed  CAS  Google Scholar 

  50. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991;115:455–6.

    PubMed  CAS  Google Scholar 

  51. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology. 1995;6:227–31.

    Article  PubMed  CAS  Google Scholar 

  52. Matthews KA, Kullr LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143:971–8.

    PubMed  CAS  Google Scholar 

  53. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–13.

    Article  PubMed  CAS  Google Scholar 

  54. Zweifel JE, O’Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189–212.

    Article  PubMed  CAS  Google Scholar 

  55. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life. Consensus statement update. JAMA. 1997;278:1186–90.

    Article  PubMed  CAS  Google Scholar 

  56. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA. 1992;267:1478–83.

    Article  PubMed  CAS  Google Scholar 

  57. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914–9.

    Article  PubMed  CAS  Google Scholar 

  58. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264:2524–8.

    Article  PubMed  CAS  Google Scholar 

  59. Simon GE. Psychiatric disorder and functional somatic symptoms as predictors of health care use. Psychiatr Med. 1992;10:49–59.

    PubMed  CAS  Google Scholar 

  60. Katon W, Berg AO, Robins AJ, Risse S. Depression—medical utilization and somatization. West J Med. 1986;144:564–8.

    PubMed  CAS  Google Scholar 

  61. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA. 1995;274:1511–7.

    Article  PubMed  CAS  Google Scholar 

  62. Whooley MA, Browner WS. Association between depressive symptoms and mortality in older women. Arch Int Med. 1998;158:2129–35.

    Article  CAS  Google Scholar 

  63. Bryant HU, Dere WH. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med. 1998;217:45–52.

    PubMed  CAS  Google Scholar 

  64. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–7.

    Article  PubMed  CAS  Google Scholar 

  65. Hot T, Cox MB, Bryant HU, Draper MW. Selective estrogen receptor modulators and postmenopausal women’s health. J Women’s Health. 1997;6:523–31.

    Google Scholar 

  66. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res. 1997;48:155–63.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Mary A. Whooley MD.

Additional information

The members of the Study of Osteoporotic Fractures Research Group are listed in the Appendix.

Dr. Whooley is supported by a Research Career Development Award from the Department of Veterans Affairs Health Services Research and Development Service. This study was supported by a grant from the American Federation for Aging Research and by Public Health Service grants AG05394, AG05407, AR35582, AR35583, AR35584, and NS36016.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whooley, M.A., Grady, D., Cauley, J.A. et al. Postmenopausal estrogen therapy and depressive symptoms in older women. J GEN INTERN MED 15, 535–541 (2000). https://doi.org/10.1046/j.1525-1497.2000.04029.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.2000.04029.x

Key words

Navigation